1. Home
  2. SPOK vs ATYR Comparison

SPOK vs ATYR Comparison

Compare SPOK & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPOK
  • ATYR
  • Stock Information
  • Founded
  • SPOK 2004
  • ATYR 2005
  • Country
  • SPOK United States
  • ATYR United States
  • Employees
  • SPOK N/A
  • ATYR N/A
  • Industry
  • SPOK Telecommunications Equipment
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SPOK Telecommunications
  • ATYR Health Care
  • Exchange
  • SPOK Nasdaq
  • ATYR Nasdaq
  • Market Cap
  • SPOK 318.9M
  • ATYR 290.6M
  • IPO Year
  • SPOK 1992
  • ATYR 2015
  • Fundamental
  • Price
  • SPOK $16.54
  • ATYR $3.34
  • Analyst Decision
  • SPOK Hold
  • ATYR Strong Buy
  • Analyst Count
  • SPOK 1
  • ATYR 6
  • Target Price
  • SPOK $15.00
  • ATYR $18.60
  • AVG Volume (30 Days)
  • SPOK 180.4K
  • ATYR 1.1M
  • Earning Date
  • SPOK 04-30-2025
  • ATYR 05-07-2025
  • Dividend Yield
  • SPOK 7.54%
  • ATYR N/A
  • EPS Growth
  • SPOK N/A
  • ATYR N/A
  • EPS
  • SPOK 0.77
  • ATYR N/A
  • Revenue
  • SPOK $139,038,000.00
  • ATYR N/A
  • Revenue This Year
  • SPOK $2.26
  • ATYR $551.06
  • Revenue Next Year
  • SPOK $0.14
  • ATYR $2,144.84
  • P/E Ratio
  • SPOK $21.51
  • ATYR N/A
  • Revenue Growth
  • SPOK N/A
  • ATYR N/A
  • 52 Week Low
  • SPOK $13.55
  • ATYR $1.42
  • 52 Week High
  • SPOK $17.96
  • ATYR $4.66
  • Technical
  • Relative Strength Index (RSI)
  • SPOK 59.93
  • ATYR 51.21
  • Support Level
  • SPOK $13.55
  • ATYR $3.06
  • Resistance Level
  • SPOK $16.60
  • ATYR $3.67
  • Average True Range (ATR)
  • SPOK 0.61
  • ATYR 0.25
  • MACD
  • SPOK 0.21
  • ATYR 0.01
  • Stochastic Oscillator
  • SPOK 95.22
  • ATYR 46.77

About SPOK Spok Holdings Inc.

Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Share on Social Networks: